FY23 total revenues are expected to increase by approximately 2% at reported rates and approximately 2% excluding foreign exchange, consensus $47.15B.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BMY:
- Pharma Earnings: Q4 Hits and Misses in a Post-COVID-19 World
- Notable companies reporting before tomorrow’s open
- Prothena reports ‘positive’ topline Phase 1 study results for PRX005
- Bristol-Myers announces CHMP opinion recommending approval for Reblozyl
- Bristol-Myers’ Sotyktu recommended for approval in psoriasis by Europe’s CHMP